A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2007
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)
Epistemonikos ID: 6d01fe0b9ab1f95cf403cd2d0ee64fdc3afd5038
First added on: Oct 09, 2017